EGFR and neoplasm: EAI001 and EAI045 have therapeutic effects despite the C797S mutation, which were identified based on the screening of a large library of compounds targeting EGFR L858R/T790M.[159, 160] EAI045 combined with cetuximab was related with significant tumor regression in L858R/T790M‐mutant mice,[161] and also effective in L858R/T790M/C797S Ba/F3 cells and tumor xenografts.